ACAD240719C16000
- 2.56
- -0.14-5.19%
ACADIA Pharmaceuticals Newsroom
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
Acadia Pharmaceuticals (ACAD Quick QuoteACAD - Free Report) is a commercial-stage company focused on developing innovative medicines to address unmet medical needs in central nervous system (CNS) disorders and rare diseases.
TD Cowen Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $35
TD Cowen analyst Ritu Baral maintains $ACADIA Pharmaceuticals(ACAD.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success rate of 47.9%
TD Cowen Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals Is Maintained at Overweight by Morgan Stanley
ACADIA Pharmaceuticals Is Maintained at Overweight by Morgan
Morgan Stanley Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Cuts Target Price to $28
Morgan Stanley analyst Jeffrey Hung maintains $ACADIA Pharmaceuticals(ACAD.US)$ with a buy rating, and adjusts the target price from $30 to $28.According to TipRanks data, the analyst has a success
Citi Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $30
Citi analyst David Hoang maintains $ACADIA Pharmaceuticals(ACAD.US)$ with a buy rating, and maintains the target price at $30.According to TipRanks data, the analyst has a success rate of 60.0% and
Optimistic Long-Term Outlook for ACADIA Pharmaceuticals' Daybue Drives Buy Rating
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Could Be Less Than A Year Away From Profitability
We feel now is a pretty good time to analyse ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) business as it appears the company may be on the cusp of a considerable accomplishment. ACADIA Pharmaceutical
Express News | ACADIA Pharmaceuticals Inc : BMO Initiates Coverage With Outperform Rating; Target Price $31
ACADIA Pharmaceuticals Initiated at Outperform by BMO Capital
ACADIA Pharmaceuticals Initiated at Outperform by BMO Capital
Express News | BMO Capital Initiates Coverage On ACADIA Pharmaceuticals With Outperform Rating, Announces Price Target of $31
BMO Capital Initiates ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Announces Target Price $31
BMO Capital analyst Evan Seigerman initiates coverage on $ACADIA Pharmaceuticals(ACAD.US)$ with a buy rating, and sets the target price at $31.According to TipRanks data, the analyst has a success rat
Trending Stocks Today: Rivian Automotive Surges 54.09% Post-Market
June 25th - US stocks trending post-market.Gainers: $Rivian Automotive(RIVN.US)$ shoots up 54.09% to $18.43 with a turnover of $788.03 million. $Volcon(VLCN.US)$ soars 25% to $6.95 with a turnover of
ACADIA Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/25/2024 82.97% RBC Capital $29 → $29 Reiterates Outperform → Outperform 05/10/2024 38.8% B of A Securit
RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $29
RBC Capital analyst Gregory Renza maintains $ACADIA Pharmaceuticals(ACAD.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 44.
Acadia Pharmaceuticals Presents DAYBUE Real-World Evidence And Additional Data In Rett Syndrome At The 2024 IRSF Annual Scientific Meeting
Acadia Pharmaceuticals, Inc. (NASDAQ:ACAD) today announced that interim data from the open-label real-world LOTUS study will be presented at the 2024 International Rett Syndrome Foundation (IRSF) Annu
ACADIA Pharmaceuticals Holds Successful 2024 Annual Meeting
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
U.S. drug wholesaler Cencora Inc (NYSE:COR), formerly AmerisourceBergen, is notifying affected individuals about their personal and highly sensitive medical information stolen during a cyberattack ear
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Will Probably Find It Hard To See A Huge Raise This Year
Key Insights ACADIA Pharmaceuticals to hold its Annual General Meeting on 29th of May CEO Steve Davis' total compensation includes salary of US$856.6k The overall pay is comparable to the industry